ELOX Eloxx Pharmaceuticals Inc

3,004

$1.15

$0.08

(7.48%)

Today

Watchers	3,004
52-Wk Low	$0.945
52-Wk High	$10.90

Market Cap	$3.93M
Volume (M)	8,813.00
52-Wk High	$10.90
52-Wk Low	$0.945

Fundamentals

Comparing Eloxx Pharmaceuticals (NASDAQ:ELOX) & BioCryst Pharmaceuticals (NASDAQ:BCRX)Ticker Report • about 1 month ago

Eloxx Pharmaceuticals (NASDAQ:ELOX Get Free Report) and BioCryst Pharmaceuticals (NASDAQ:BCRX Get Free Report) are both small-cap medical companies, but which is the better...

Share to Feed

Eloxx Pharmaceuticals reports results of patient biopsy assessment by NIPOKAThe Fly • about 2 months ago

See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of ProteinuriaGlobe Newswire • about 2 months ago

Podocyte Exact Morphology Procedure Results Podocyte Exact Morphology Procedure Results ELX-02 treatment improved podocyte foot process effacement in all three patients by an...

Financial Contrast: Novozymes A/S (OTCMKTS:NVZMY) and Eloxx Pharmaceuticals (NASDAQ:ELOX)Zolmax • about 2 months ago

Novozymes A/S (OTCMKTS:NVZMY Get Free Report) and Eloxx Pharmaceuticals (NASDAQ:ELOX Get Free Report) are both basic materials companies, but which is the better investment? We will...

Eloxx Pharmaceuticals Reports Independent Confirmation of Positive Biopsy Results in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeGlobe Newswire • 2 months ago

Highly regarded renal pathologist and transmission electron microscopy (TEM) expert independently confirms previously reported qualitative assessment by Mayo Clinic of TEM biopsy scans All three...

Critical Analysis: Eloxx Pharmaceuticals (NASDAQ:ELOX) vs. Ocugen (NASDAQ:OCGN)Ticker Report • 4 months ago

Eloxx Pharmaceuticals (NASDAQ:ELOX Get Free Report) and Ocugen (NASDAQ:OCGN Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, analyst recommendations, ...

Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport SyndromeGlobe Newswire • 4 months ago

All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02 Podocyte foot process effacement is a hallmark of Alport ...

Eloxx Pharma (NASDAQ:ELOX) Rises On Promising Phase 2 Data In Alport SyndromeTipRanks Financial Blog • 4 months ago

Shares of biopharmaceutical company Eloxx Pharmaceuticals (NASDAQ:ELOX) are on the rise today after it announced positive results from a Phase 2 st... Shares of biopharmaceutical company Eloxx Pharmaceuticals (NASDAQ:ELOX) are on the rise today after it announced positive results from a Phase 2 ...

Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing RequirementGlobe Newswire • 4 months ago

WATERTOWN, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the Hearings Panel) of The Nasdaq Stock Market...

This Small Cap Stock Surged Over 100%ValueWalk • 5 months ago

Key Points Arguably the most impressive mover yesterday was a stock you have probably never heard of. Shares of Eloxx ... Read more Key Points Shares of Elox surged almost 100% after receiving an increased price target from Oppenheimer and published preclinical data demonstrating activity against ...